WO2021006822A1 - Pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy - Google Patents
Pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy Download PDFInfo
- Publication number
- WO2021006822A1 WO2021006822A1 PCT/TH2019/000021 TH2019000021W WO2021006822A1 WO 2021006822 A1 WO2021006822 A1 WO 2021006822A1 TH 2019000021 W TH2019000021 W TH 2019000021W WO 2021006822 A1 WO2021006822 A1 WO 2021006822A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- pharmaceutical compositions
- sesamin
- hesperidin
- compositions according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to the fields of chemistry and pharmaceutical science with a special relation to pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy.
- Sesamin is a major lignan as active ingredient of Sesamum indicum seeds.
- the anti-cancer effects of sesamin have been mainly attributed to its anti-proliferation, proapoptotic, anti-inflammatory, anti-metastatic, anti- and pro-angiogenic, and pro-autophagocytic activities. Dietary supplementation of sesamin has been shown to inhibit chemically-induced mammary carcinogenesis in rats (Hirose et al, Anticancer Res. 12 (4)( 1992)).
- the previous studies show that sesamin inhibits proliferation in human MCF-7 breast cancer cells by inducing cell cycle arrest at G 1 phase (Yokota et al, Cancer Sci.
- Taiwanese patent with publication number TW20061 8805A has been disclosed the use of sesamin as the hepatic cancer cell proliferation inhibitor by activating the cancer inhibition gene P53.
- These disclosed inventions show that the anti-cancer properties of sesame or sesamin extract has been well known knowledge and has been used in the actual industries.
- Hesperidin is a natural bioflavonoid found abundantly in citrus fruits and have been widely used as a nutritional supplement. Furthermore, hesperidin has been also shown to be effective exhibits anti-inflammatory antibacterial and anti-oxidative properties. Jain and Parmar, Inflamm Res. 60(5) (201 1 ). There are further demonstrated to be an effective anti-cancer agent that has been shown to induce apoptosis in human hepatocellular carcinoma HepG2 cell. Banjerdpongchai et al, Tumor Biol. 637( 1 ) (2016) probably through caspase activation. From previous study dietary hesperidin inhibits carcinogenesis in the lung in rat model. Kamaraj et al, Fundam Clin Parmacol. 25( 1 ) (201 1).
- chemotherapeutic agent can prolong the patient’s life and potentially rid them of the cancer.
- doxorubicin is antibiotic of the anthracycline group are used in oncological diseases including lung cancer, breast cancer, and leucosis, are common and carry a high mortality rate. DOX non-covalently binds to DNA, blocking the synthesis of nucleic acid, but exert toxic effect in normal tissues and cells. Flowever, side effects are unpredictable and cause suffering physically to the patients. (Menna et al, Expert Opin Drug Saf. 1 1 (2012)). The most common side effects of chemotherapeutics agent are illness, easy bruising or breeding, weakened immune system and hair loss.
- the present disclosed invention is combination of sesamin, hesperidin that bring several advantages for cancer therapy, such as synergistic therapeutic effect for improving therapeutic efficacy, minimized side effects and reduce overcoming drug resistance.
- compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy which synergistically to inhibit cancer cells growth.
- the pharmaceutical composition comprises at least sesamin, flavonoid compound that preferably hesperidin and chemotherapeutic agent. Development status the drug combination has been evaluated in human breast cancer model (in vitro cell culture assays) shown to be much more effective than individual treatments alone in terms of cytotoxicity.
- the aim of the present disclosed invention is to increase cancer treatment efficacy, minimize the risk of resistance that finally lower drug concentrations are required to decrease the side effect in normal cells.
- Fig. l shown the structure of doxorubicin
- Fig.2 shown the dose/response curves for doxorubicin alone (upper), hesperidin alone (middle) and sesamin alone (lower) on the breast cancer cells.
- Fig.3 shown the dose/response curve for combination of hesperidin and sesamin on the breast cancer cells.
- Fig.4 shown the dose/response curve indicating synergistic of hesperidin, sesamin and the chemotherapeutic agent (doxorubicin) on the breast cancer cells.
- the present invention provides the composition for the synergistic treatment of cancer comprising administering a synergistically, the therapeutically effective amount of sesamin, flavonoid compound and chemotherapeuti c agents.
- the term“synergistic” means that the effect achieved with the method and composition of this invention is greater than the sum of the effects that result from the method and composition comprising sesamin or flavonoid compound or chemotherapeutic agent separately. Combination therapy using these agents should enhance the response rate of different cancers to these drugs.
- this synergistic effect should significantly reduce side effects by permitting a lower therapeutic dose to be administered for oncological patients of these kind of cancer that is selected from leukemia, muscle tumor, bone cancer, lymphoma, melanoma, ovarian cancer, skin cancer, testicular cancer, stomach cancer, pancreatic cancer, kidney cancer, Breast cancer, prostate cancer, rectal cancer, cancer of the head and neck, brain cancer, esophageal cancer, bladder cancer, adrenocortical carcinoma, lung cancer, bronchial cancer, endometrial cancer, cervical cancer or liver cancer.
- the sesamin can be selected from synthetic sesamin or extracted sesamin from sesame ( Sesamum indicum ) seeds wherein said sesamin is dissolved in organic solvent that can be selected from chloroform, methanol, ethanol, oil or DMSO or combination thereof, most preferably dissolved in DMSO.
- the flavonoid compound can be selected from anthocyanins or chalcones or flavonones or flavones or flavonols or isoflavonoids or combination thereof wherein said flavonoid compound is preferably flavonones, and most preferably hesperidin.
- Said hesperidin can be selected from synthetic hesperidin or extracted hesperidin from citrus fruits.
- said hesperidin is dissolved in the solvent that can be selected from chloroform, methanol, ethanol, oil, water or DMSO or combination thereof, most preferably dissolved in DMSO.
- the chemotherapeutic agents is selected from the group consisting of paclitaxel, irinotecan HC1, docitaxel, doxorubicin, Danubicin (daunorubicin), epirubicin, 5-fluorouracil, melphalan, cis- platin, carboplatin, cyclophosphamide (cyclophosphamide), mitomycin, methotrexate, mitoxantrone, vinblastine, vincristine, ifosfamide, ghost Teniposide, etoposide, bleomycin, leucovorin, cytarabine, dactinomycin, a- Interferon alpha, streptozocin, prednisolone or procarbazine HC1.
- the most preferable of said chemotherapeutic agent according to this invention is doxorubicin that most preferably dissolved in DMSO.
- the human breast carcinoma cell line (MDA-MB231) were cultured in media containing 10% FBS.
- MDA-MB231 cells were plated in 96 well plates at a density of 5x10 3 cells per well for overnight for testing with therapeutic composition designated herein as flavonoid compound (hesperidin), sesamin and known chemotherapeutic agent (doxorubicin) for 24 h. After 24 h, the incubated in 0.5 mg/ml MTT at 37°C for 4 h. A solubilization solution, 200 m ⁇ of DMSO (dimethyl sulfoxide), was added to each well and absorption values read at 540 on microplate reader. %Cell viability (ODtest/ODcontrol)xlOO
- Doxorubicin is a member of anthracycline antibiotic family of chemotherapeutics. It acts by intercalating DNA so that DNA synthesis cannot occur. The tumor cells cannot reproduce and should become the dead cells.
- the chemical structure of said doxorubicin is provided in Fig. l .
- the MDA-MB23 1 were tested against hesperidin or/and sesamin or/and doxorubicin individually at a various concentration and against the combination therapeutic containing all agents
- Fig. 2 After 24-hour treatment with hesperidin alone or sesamin alone and doxorubicin alone are shown in Fig. 2.
- Doxorubicin demonstrated cytotoxicity on MDA-MB231 in a dose-dependent manner.
- Fig 2 (Middle), a dose/response curve is shown for hesperidin alone on MDA-MB231 for 24 h using MTT assay.
- Hesperidin treatment suppression cell growth in MDA- MB231 and the twenty percent inhibitory hesperidin dose was found to be 118.18 mM in 24 h.
- Fig 2 a standard dose/response curve is shown for sesamin alone on MDA-MB231 for 24 h using MTT assay. As shown in figure 2 sesamin treatment suppression cell growth in MDA-MB231 and the twenty percent inhibitory sesamin dose was found to be 154.12 mM in 24 h.
- the data of inhibiton concentration of doxorubicin, hesperidin and sesamin are given in tables 1.
Abstract
Pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy is disclosed which synergistically to inhibit cancer cells growth. The pharmaceutical composition comprises at least sesamin, flavonoid compound that preferably hesperidin and chemotherapeutic agent. Development status the drug combination has been evaluated in human breast cancer model (in vitro cell culture assays) shown to be much more effective than individual treatments alone in terms of cytotoxicity. The aim of the present disclosed invention is to increase cancer treatment efficacy, minimize the risk of resistance that finally lower drug concentrations are required to decrease the side effect in normal cells.
Description
Title of invention
PHARMACEUTICAL COMPOSITIONS HAVING SYNERGISTIC EFFECTS OF
NATURAL EXTRACTS FOR CANCER TREATMENT UNDERGOING CHEMOTHERAPY
Field of the invention
The invention relates to the fields of chemistry and pharmaceutical science with a special relation to pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy.
Background of the invention
Sesamin is a major lignan as active ingredient of Sesamum indicum seeds. There have been numerous studied of anti-cancer properties of sesamin. The anti-cancer effects of sesamin have been mainly attributed to its anti-proliferation, proapoptotic, anti-inflammatory, anti-metastatic, anti- and pro-angiogenic, and pro-autophagocytic activities. Dietary supplementation of sesamin has been shown to inhibit chemically-induced mammary carcinogenesis in rats (Hirose et al, Anticancer Res. 12 (4)( 1992)). The previous studies show that sesamin inhibits proliferation in human MCF-7 breast cancer cells by inducing cell cycle arrest at G 1 phase (Yokota et al, Cancer Sci. 98(9) (2007)) and Sesamin has also been reported to inhibit matrix metalloproteinase-9 (MMP-9) activity (Lee et al, Inflammation. 34(3) (201 1)). Further, there have been several disclosed in patent prior art relating to sesamin as the component in the pharmaceutical compositions for cancer treatment. Refer to Taiwanese patent with publication number TWI423809B, it disclosed a pharmaceutical composition for treating or ameliorating a disease such as cancers or overactive bladder by inhibiting acetylcholine receptor activity. Said pharmaceutical compositions comprises an effective amount of a sesame extract and a pharmaceutical acceptable carrier. It might further comprise a chemotherapeutic agent. Moreover, there is also Taiwanese patent with publication number TW20061 8805A has been disclosed the use of sesamin as the hepatic cancer cell proliferation inhibitor by activating the cancer inhibition gene P53. These disclosed inventions show that the anti-cancer properties of sesame or sesamin extract has been well known knowledge and has been used in the actual industries.
Hesperidin is a natural bioflavonoid found abundantly in citrus fruits and have been widely used as a nutritional supplement. Furthermore, hesperidin has been also shown to be effective exhibits anti-inflammatory antibacterial and anti-oxidative properties. Jain and Parmar, Inflamm Res. 60(5)
(201 1 ). There are further demonstrated to be an effective anti-cancer agent that has been shown to induce apoptosis in human hepatocellular carcinoma HepG2 cell. Banjerdpongchai et al, Tumor Biol. 637( 1 ) (2016) probably through caspase activation. From previous study dietary hesperidin inhibits carcinogenesis in the lung in rat model. Kamaraj et al, Fundam Clin Parmacol. 25( 1 ) (201 1).
In cancer or malignant patients, chemotherapeutic agent can prolong the patient’s life and potentially rid them of the cancer. For example, doxorubicin (DOX) is antibiotic of the anthracycline group are used in oncological diseases including lung cancer, breast cancer, and leucosis, are common and carry a high mortality rate. DOX non-covalently binds to DNA, blocking the synthesis of nucleic acid, but exert toxic effect in normal tissues and cells. Flowever, side effects are unpredictable and cause suffering physically to the patients. (Menna et al, Expert Opin Drug Saf. 1 1 (2012)). The most common side effects of chemotherapeutics agent are illness, easy bruising or breeding, weakened immune system and hair loss. Therefore, there are many studies in relation to using other substances that have been prove as medical safe to combine with chemotherapeutic agent to reduce its treatment dosage, but still efficiently treat the cancer patients. The present disclosed invention is combination of sesamin, hesperidin that bring several advantages for cancer therapy, such as synergistic therapeutic effect for improving therapeutic efficacy, minimized side effects and reduce overcoming drug resistance.
Summary of the invention
Pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy is disclosed which synergistically to inhibit cancer cells growth. The pharmaceutical composition comprises at least sesamin, flavonoid compound that preferably hesperidin and chemotherapeutic agent. Development status the drug combination has been evaluated in human breast cancer model (in vitro cell culture assays) shown to be much more effective than individual treatments alone in terms of cytotoxicity.
The aim of the present disclosed invention is to increase cancer treatment efficacy, minimize the risk of resistance that finally lower drug concentrations are required to decrease the side effect in normal cells.
Brief description of the drawings
Fig. l shown the structure of doxorubicin
Fig.2 shown the dose/response curves for doxorubicin alone (upper), hesperidin alone (middle) and sesamin alone (lower) on the breast cancer cells.
Fig.3 shown the dose/response curve for combination of hesperidin and sesamin on the breast cancer cells.
Fig.4 shown the dose/response curve indicating synergistic of hesperidin, sesamin and the chemotherapeutic agent (doxorubicin) on the breast cancer cells.
Detailed description of the invention
Advantageously, the present invention provides the composition for the synergistic treatment of cancer comprising administering a synergistically, the therapeutically effective amount of sesamin, flavonoid compound and chemotherapeuti c agents. The term“synergistic” means that the effect achieved with the method and composition of this invention is greater than the sum of the effects that result from the method and composition comprising sesamin or flavonoid compound or chemotherapeutic agent separately. Combination therapy using these agents should enhance the response rate of different cancers to these drugs. Further, this synergistic effect should significantly reduce side effects by permitting a lower therapeutic dose to be administered for oncological patients of these kind of cancer that is selected from leukemia, muscle tumor, bone cancer, lymphoma, melanoma, ovarian cancer, skin cancer, testicular cancer, stomach cancer, pancreatic cancer, kidney cancer, Breast cancer, prostate cancer, rectal cancer, cancer of the head and neck, brain cancer, esophageal cancer, bladder cancer, adrenocortical carcinoma, lung cancer, bronchial cancer, endometrial cancer, cervical cancer or liver cancer.
The sesamin can be selected from synthetic sesamin or extracted sesamin from sesame ( Sesamum indicum ) seeds wherein said sesamin is dissolved in organic solvent that can be selected from chloroform, methanol, ethanol, oil or DMSO or combination thereof, most preferably dissolved in DMSO.
The flavonoid compound can be selected from anthocyanins or chalcones or flavonones or flavones or flavonols or isoflavonoids or combination thereof wherein said flavonoid compound is preferably flavonones, and most preferably hesperidin. Said hesperidin can be selected from synthetic
hesperidin or extracted hesperidin from citrus fruits. Moreover, said hesperidin is dissolved in the solvent that can be selected from chloroform, methanol, ethanol, oil, water or DMSO or combination thereof, most preferably dissolved in DMSO.
The chemotherapeutic agents is selected from the group consisting of paclitaxel, irinotecan HC1, docitaxel, doxorubicin, Danubicin (daunorubicin), epirubicin, 5-fluorouracil, melphalan, cis- platin, carboplatin, cyclophosphamide (cyclophosphamide), mitomycin, methotrexate, mitoxantrone, vinblastine, vincristine, ifosfamide, ghost Teniposide, etoposide, bleomycin, leucovorin, cytarabine, dactinomycin, a- Interferon alpha, streptozocin, prednisolone or procarbazine HC1. The most preferable of said chemotherapeutic agent according to this invention is doxorubicin that most preferably dissolved in DMSO.
Example
The human breast carcinoma cell line (MDA-MB231) were cultured in media containing 10% FBS. MDA-MB231 cells were plated in 96 well plates at a density of 5x103 cells per well for overnight for testing with therapeutic composition designated herein as flavonoid compound (hesperidin), sesamin and known chemotherapeutic agent (doxorubicin) for 24 h. After 24 h, the incubated in 0.5 mg/ml MTT at 37°C for 4 h. A solubilization solution, 200 mΐ of DMSO (dimethyl sulfoxide), was added to each well and absorption values read at 540 on microplate reader. %Cell viability (ODtest/ODcontrol)xlOO
Doxorubicin is a member of anthracycline antibiotic family of chemotherapeutics. It acts by intercalating DNA so that DNA synthesis cannot occur. The tumor cells cannot reproduce and should become the dead cells. The chemical structure of said doxorubicin is provided in Fig. l .
The MDA-MB23 1 were tested against hesperidin or/and sesamin or/and doxorubicin individually at a various concentration and against the combination therapeutic containing all agents
The results
After 24-hour treatment with hesperidin alone or sesamin alone and doxorubicin alone are shown in Fig. 2. Doxorubicin demonstrated cytotoxicity on MDA-MB231 in a dose-dependent manner. In Fig 2 (Middle), a dose/response curve is shown for hesperidin alone on MDA-MB231 for
24 h using MTT assay. As shown in figure 2 Hesperidin treatment suppression cell growth in MDA- MB231 and the twenty percent inhibitory hesperidin dose was found to be 118.18 mM in 24 h. In Fig 2 (Lower), a standard dose/response curve is shown for sesamin alone on MDA-MB231 for 24 h using MTT assay. As shown in figure 2 sesamin treatment suppression cell growth in MDA-MB231 and the twenty percent inhibitory sesamin dose was found to be 154.12 mM in 24 h. The data of inhibiton concentration of doxorubicin, hesperidin and sesamin are given in tables 1.
Table 1 IC 10, IC20 and IC50 drug value in MDA-MB231 cells at 24 h
The same methods described above were used for this experiment this study was repeated four times once with exposing IC20 sesamin plus the increasing dose of hesperidin, once with IC2G of hesperidin plus the increasing dose of sesamin. The results show that exposing IC20 of hesperidin plus the increasing dose of sesamin a greater activity than exposing IC20 sesamin plus the increasing dose of hesperidin and compound alone in the same dose shown in figure 3. The data of inhibiton concentration of hesperidin combined with sesamin are given in tables 2
Table 2 IC10, IC20 and IC50 value of Hesperidin combined with sesamin in MDA-MB231 cells at 24 h
The same methods described above were used for this experiment this study was repeated four times once with exposing 50 mM hesperidin plus the increasing dose of doxorubicin, once with
exposing 50 mM sesamin plus the increasing dose of doxorubicin and once exposing IC 10 of hesperidin and IC10 of sesamin plus the increasing dose of doxorubicin. The results show that exposing IC10 ofhesperidin I C 10 of sesamin plus the increasing dose of doxorubicin a greater activity than compound alone and combined with hesperidin and doxorubicin combined with sesamin and doxorubicin shown in figure 4. The experiment support that the synergy between the effect of hesperidin or sesamin and doxorubicin, inducing cell death in human breast cancer.The data of inhibiton concentration (IC) of Hesperidin or/and sesamin combined with drug (doxorubicin) in hesperidin and sesamin are given in tables 3.
Table 3 IC 10, IC20 and IC50 value of Hesperidin or/and sesamin combined with the drug (doxorubicin) in MDA-MB231 cells at 24 h
Although, this invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while several variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. It should be understood that various features and aspects of the disclosed embodiments can be combined with, or substituted for, one another in order to form varying modes of the disclosed invention. Therefore, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only be a fair reading of the claims that follow.
Claims
1. Pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy comprises at least an effective amount of sesamin, flavonoid compound and chemotherapeutic agents.
2. The pharmaceutical compositions according to claim 1 wherein sesamin is synthetic sesamin or extracted sesamin from sesame seed.
3. The pharmaceutical compositions according to any claim of claim 1 or 2 wherein sesamin is dissolved in organic solvent that can be selected from chloroform, methanol, ethanol, oil or DMSO or combination thereof.
4. The pharmaceutical compositions according to claim 1 wherein flavonoid compound can be selected from anthocyanins or chalcones or flavonones or flavones or flavonols or isoflavonoids or combination thereof.
5. The pharmaceutical compositions according to any claims of claim 1 or 4 wherein flavonoid is preferably flavonones.
6. The pharmaceutical compositions according to any claims of claim 1 , 4 or 5 wherein flavonoid is suitably hesperidin.
7. The pharmaceutical compositions according to claim 6 wherein hesperidin is synthetic hesperidin or extracted hesperidin from citrus fruits.
8. The pharmaceutical compositions according to claim 7 wherein hesperidin is dissolved in solvent that can be selected from chloroform, methanol, ethanol, oil, water or DMSO or combination thereof.
9. The pharmaceutical compositions according to claim 1 wherein chemotherapeutic agent is selected from the group consisting of paclitaxel, irinotecan HC1, docitaxel, doxorubicin, Danubicin (daunorubicin), epirubicin, 5-fluorouracil, melphalan, cis-platin, carboplatin, cyclophosphamide (cyclophosphamide), mitomycin, methotrexate, mitoxantrone, vinblastine, vincristine, ifosfamide, ghost Teniposide, etoposide, bleomycin, leucovorin, cytarabine, dactinomycin, a- Interferon alpha, streptozocin, prednisolone or procarbazine HC1.
10. The pharmaceutical compositions according to claim 1 wherein chemotherapeutic agent is suitably doxorubicin.
1. The pharmaceutical compositions according to claim 1 wherein said composition is provided for treating the cancer which selected from leukemia, muscle tumor, bone cancer, lymphoma, melanoma, ovarian cancer, skin cancer, testicular cancer, stomach cancer, pancreatic cancer, kidney cancer, Breast cancer, prostate cancer, rectal cancer, cancer of the head and neck, brain cancer, esophageal cancer, bladder cancer, adrenocortical carcinoma, lung cancer, bronchial cancer, endometrial cancer, cervical cancer or liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TH2019/000021 WO2021006822A1 (en) | 2019-07-08 | 2019-07-08 | Pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TH2019/000021 WO2021006822A1 (en) | 2019-07-08 | 2019-07-08 | Pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021006822A1 true WO2021006822A1 (en) | 2021-01-14 |
Family
ID=74114801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TH2019/000021 WO2021006822A1 (en) | 2019-07-08 | 2019-07-08 | Pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2021006822A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113181172A (en) * | 2021-06-08 | 2021-07-30 | 隋雨桐 | Application of sesamin in preparation of product for treating and/or preventing lymphoma |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637610A (en) * | 1991-06-15 | 1997-06-10 | Suntory Limited | Composition containing dioxabicyclo [3.3.0] octane derivative |
| US20040014721A1 (en) * | 2002-06-10 | 2004-01-22 | Oklahoma Medical Research Foundation | Method for using tethered bis(polyhydroxyphenyls) and O-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| KR20080098814A (en) * | 2007-05-07 | 2008-11-12 | 한국과학기술연구원 | Pharmaceutical composition containing extracts of acanthopanax chiisanensis or lignan compounds isolated from thereof for anticancer agent assistant |
| JP2010150209A (en) * | 2008-12-26 | 2010-07-08 | Suntory Holdings Ltd | Composition containing sesamins and epigallocatechin gallate |
| US20100311676A1 (en) * | 2007-12-28 | 2010-12-09 | Suntory Holdings Limited | Compositions containing sesamin-class compound(s) and quercetin glycoside(s) |
-
2019
- 2019-07-08 WO PCT/TH2019/000021 patent/WO2021006822A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637610A (en) * | 1991-06-15 | 1997-06-10 | Suntory Limited | Composition containing dioxabicyclo [3.3.0] octane derivative |
| US20040014721A1 (en) * | 2002-06-10 | 2004-01-22 | Oklahoma Medical Research Foundation | Method for using tethered bis(polyhydroxyphenyls) and O-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| KR20080098814A (en) * | 2007-05-07 | 2008-11-12 | 한국과학기술연구원 | Pharmaceutical composition containing extracts of acanthopanax chiisanensis or lignan compounds isolated from thereof for anticancer agent assistant |
| US20100311676A1 (en) * | 2007-12-28 | 2010-12-09 | Suntory Holdings Limited | Compositions containing sesamin-class compound(s) and quercetin glycoside(s) |
| JP2010150209A (en) * | 2008-12-26 | 2010-07-08 | Suntory Holdings Ltd | Composition containing sesamins and epigallocatechin gallate |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113181172A (en) * | 2021-06-08 | 2021-07-30 | 隋雨桐 | Application of sesamin in preparation of product for treating and/or preventing lymphoma |
| CN113181172B (en) * | 2021-06-08 | 2022-08-02 | 隋雨桐 | Application of sesamin in preparation of product for treating and/or preventing lymphoma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2538218C (en) | Compositions of botanical extracts for cancer therapy | |
| du Plessis-Stoman et al. | Combination treatment with oxaliplatin and mangiferin causes increased apoptosis and downregulation of NFκB in cancer cell lines | |
| Chen et al. | Effects of Ginkgo biloba extract EGb761 on human colon adenocarcinoma cells | |
| Salim et al. | Antitumoral and antioxidant potential of Egyptian propolis against the PC3 prostate cancer cell line | |
| Hsiao et al. | The tumor-growth inhibitory activity of flavanone and 2′-OH flavanone in vitro and in vivo through induction of cell cycle arrest and suppression of cyclins and CDKs | |
| Gacche et al. | In vitro evaluation of anticancer and antimicrobial activity of selected medicinal plants from Ayurveda | |
| Jit et al. | Phytochemicals: A potential next generation agent for radioprotection | |
| Upadhyay et al. | Methyl-β-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: Involvement of Akt, NF-κB and Bcl-2 | |
| Sun et al. | Antitumor effects of chrysanthemin in PC-3 human prostate cancer cells are mediated via apoptosis induction, caspase signalling pathway and loss of mitochondrial membrane potential | |
| WO2021006822A1 (en) | Pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy | |
| Gupta et al. | Beating cancer with natural plant sources | |
| Shirzad et al. | The effects of hesperetin on apoptosis induction and inhibition of cell proliferation in the prostate cancer PC3 cells | |
| CN101428034B (en) | Antineoplastic combined medicament with enhancing and poison-reducing character | |
| Zhao et al. | Phytochemicals and mitochondria: Therapeutic allies against gastric cancer | |
| Hahm et al. | Extracts of opuntia humifusa fruits inhibit the growth of ags human gastric adenocarcinoma cells | |
| Cheng et al. | The potential of neural stem cell as vehicle to deliver quercus infectoria extract to glioma cell in vitro | |
| El-burai et al. | Anticancer activity of Rosemary (Rosmarinus officinalis L.) and oats (Avena sativa L.) extracts, and their antitumor enhancement of 5-fluorouracil on Colon Cancer Caco-2 cell line | |
| Kasiram et al. | Combination therapy of cisplatin and other agents for osteosarcoma: a review | |
| Plessis-Stoman et al. | Combination treatment with oxyplatlin and mangiferin causes increased apoptosis and downregulation of NFKB in cancer cell lines | |
| Hassan et al. | Synergistic Effect of the Combination of Polyphenols with Gemcitabineon Pancreatic Cancer Cell line AsPC-1 | |
| Koneru et al. | Natural products against drug-induced cardiotoxicity | |
| Alabbasy et al. | Histological study of the effect of some oncology drugs on heart muscle | |
| Kadhim et al. | Cytotoxic activities of ferulago abbreviata total flavonoid extract on three different cancer cell lines | |
| Sivakali et al. | Cytotoxic Activity of Cardiospermum halicacabum L. against Oral Cancer Cell Lines.-SCC25 | |
| AlMalki | Cytotoxic Activities of Phytochemical Components from Ethanol Extract of Ajwa Date on Human Hepatoma Cancer Cells in Vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19936762 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 19936762 Country of ref document: EP Kind code of ref document: A1 |